

17465DIV(AP)
Serial No. 10/783,325
Filed: February 20, 2004

PATENT

REMARKS

In response to a requirement made by the Examiner, Applicants elected to prosecute the invention defined by claims 1-41 and 47-50. Furthermore, the applicants elected the compound of claim 40, i.e. [(N-morpholinyl phenylamino)-methylene]-1, 3-dihydroindol-2-one. (Note this compound was incorrectly named in the Response of 3 June 2005.)

The Examiner has now rejected all of the claims under 35 USC § 102(b) as anticipated by Walter et al (2000). Applicants have now amended claim 1 to delete R¹ is NO₂ and R² is phenyl. This amendment overcomes the Examiner's rejection.

The Examiner has also rejected claims 1-41 and 47-50 under 35 USC § 102(a) as anticipated by Glennon et al.

The Applicants have amended the claims to overcome the rejection by deleting R¹ is bromine.

The Examiner has rejected claims 1-41 and 47-50 for obviousness-type double patenting over U.S. 6,765,012. This rejection is now overcome by filing a Terminal Disclaimer herewith.

17465DIV(AP)
Serial No. 10/783,325
Filed: February 20, 2004

PATENT

The applicants believe that the present amendment overcomes the Examiner's rejections of the claims. The Examiner is asked to reconsider and withdraw the rejections and pass the patent application to issuance.

Respectfully submitted,

Date: 8/17/05

RJ Baran
Robert J. Baran
Reg. No. 25,806
ALLERGAN, INC.
T2-7H
2525 Dupont Drive
Irvine, CA 92612
Tel: 714-246-4669
Fax: 714-246-4249

CERTIFICATE OF FAX TRANSMISSION	
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING TRANSMITTED TO THE CENTRAL FAX	
NUMBER 571-273-8300, ON AUGUST 18, 2005 (Date) Name of person making deposit: <u>Bonnie Ferguson</u>	
Signature: <u>Bonnie Ferguson</u>	Date: <u>8/18/2005</u>